Skip to main content
SpringerLink
Log in

Data Monitoring for the Aspirin Component of the Physicians’ Health Study: Issues in Early Termination for a Major Secondary Endpoint

  • Chapter
Data Monitoring in Clinical Trials

  • 1320 Accesses

Abstract

The Physicians’ Health Study was a randomized, double-blind, placebo controlled, 2 #x00D7; 2 factorial primary prevention trial whose primary aims were to test whether aspirin reduces risks of cardiovascular disease (CVD) mortality and beta-carotene decreases the incidence of cancer. The trial was conducted among 22,071 apparently healthy U.S. male physicians aged 40–84 years at entry. After five years of treatment and follow-up, on December 17, 1987, the independent Data and Safety Monitoring Board (DSMB) recommended unanimously the early termination of the aspirin component due principally to the emergence of a statistically extreme (p < 0.00001) 47% reduction in risk of a first myocardial infarction (MI), the major secondary endpoint, in the context of a far lower than anticipated CVD mortality as well as use of aspirin among the vast majority of individuals who experienced a non-fatal event. Several additional factors were involved, including little or no trend in either CVD mortality or stroke, although the numbers of events were too low to distinguish between small benefit, no effect, and small harm. These circumstances suggested clear evidence for aspirin in preventing a first MI, a major outcome of clinical and public health importance in the context of inadequate power to test the primary endpoint of CVD mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Williams A, Hennekens CH. 2004. The role of aspirin in cardiovascular diseases-forgotten benefits? Expert Opin Pharmacother 5:109–115.

    Article  Google Scholar 

  2. Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol 231:232–235.

    Google Scholar 

  3. Hennekens CH, Karlson LK, Rosner B. 1978. A case control study of regular aspirin use and coronary deaths. Circulation 58:35–38.

    Google Scholar 

  4. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. 1991. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 266:521–527.

    Article  Google Scholar 

  5. Friedman LM, Furberg CD, DeMets DL. 1998. Fundamentals of Clinical Trials. Third Edition, Springer-Verlag, New York.

    Google Scholar 

  6. Hennekens CH, Buring JE. 1986. Epidemiology in Medicine. Little, Brown & Company, Boston.

    Google Scholar 

  7. Hennekens CH, Buring JE, Manson J, Ridker PM. 1999. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. W Saunders Company, Philadelphia.

    Google Scholar 

  8. Antiplatelet Trialists Collaboration. 1988. Secondary prevention of vascular disease by prolonged anti-platelet therapy. BMJ 296:320–332.

    Article  Google Scholar 

  9. Peto R, Doll R, Buckley JD, Sporn M. 1981. Can dietary beta-carotene materially reduce human cancer rates? Nature 290:201–205.

    Article  Google Scholar 

  10. Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. 1985. The 2 x 2 factorial design: Its application to a randomized trial of aspirin and beta-carotene in U.S. physicians. Stat Med 4:111–115.

    Article  Google Scholar 

  11. Hennekens CH, Eberlein K for the Physicians’ Health Study Research Group. 1985. A randomized trial of aspirin and beta-carotene among US physicians Prev Med 14:165–168.

    Google Scholar 

  12. Haybittle JL. 1971. Repeated assessment of results in clinical trails of cancer treatment. Br J Radiol 44:793–797.

    Article  Google Scholar 

  13. Peto R, Pike ML, Armitage P, Breslow NE, Cox DR, Howard SV, et al. 1976. Design and analysis of randomized clinical trails requiring prolonged observations of each patient. I. Introduction and design. Br J Ca 34:585–612.

    Article  Google Scholar 

  14. Data Monitoring Board of the Physicians’ Health Study: Cairns J, Cohen L, Colton T, DeMets DL, Deykin D, Friedman L, Greenwald P, Hutchison GB, Rosner B. 1991. Issues in the early termination of the aspirin component. Ann Epidemiol 1:395–405.

    Article  Google Scholar 

  15. Steering Committee of the Physicians’ Health Study Research Group. 1988. Preliminary report: Findings from the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 318:262–264.

    Article  Google Scholar 

  16. Lan KKG, Simon R, Halperin M. 1982. Stochastically curtailed tests in long-term clinical trials. Comm Stat 1:207–219.

    MathSciNet  MATH  Google Scholar 

  17. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. 1988. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 296:313–316.

    Article  Google Scholar 

  18. Hennekens CH, Peto R, Hutchison GB, Doll R. 1988. An overview of the British and American aspirin studies. N Engl J Med 318:923–924.

    Article  Google Scholar 

  19. Steering Committee of the Physicians’ Health Study Research Group. 1989. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129–135.

    Article  Google Scholar 

  20. The Medical Research Council’s General Practice Research Framework. 1998. Thrombosis prevention trials: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 351:233–240.

    Article  Google Scholar 

  21. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, et al. 1998. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755–1762.

    Article  Google Scholar 

  22. Collaborative Group of the Primary Prevention Project. 2001. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357:89–95.

    Article  Google Scholar 

  23. Eidelman RS, Hebert PR, Weisman S, Hennekens CH. 2003. An update on aspirin in the primary prevention of cardiovascular disease Arch. Intern Med 163:2006–2010.

    Article  Google Scholar 

  24. Cook N, Hebert P, Manson J, Buring J, Hennekens CH. 2000. Self-selected post-trial aspirin use and subsequent cardiovascular disease and mortality in the Physicians’ Health Study. Arch Intern Med 160:921–928.

    Article  Google Scholar 

  25. Cole S, Cook N, Hennekens CH. 2002. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study. Am J Epidemiol 155:1045–1053.

    Article  Google Scholar 

  26. Coronary Drug Project Research Group. 1981. Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study. Control Clin Trials 1:363–76.

    Article  Google Scholar 

  27. United States Preventive Services Task Force. 2002. Aspirin for the primary prevention of cardiovascular events; recommendation and rationale. Ann Intern Med 136:157–160.

    Google Scholar 

  28. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. 2002. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388–391.

    Article  Google Scholar 

  29. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. 2005. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin

    David L. DeMets

  2. University of Miami School of Medicine and Florida Atlantic University, Boca Raton, Florida

    Charles H. Hennekens

Authors
  1. David L. DeMets
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles H. Hennekens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biostatistics and Medical Informatics, University of Wisconsin Medical School, Madison, WI, 53972-4675, USA

    David L. DeMets

  2. Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA

    Curt D. Furberg

  3. Bethesda, MD, USA

    Lawrence M. Friedman

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

DeMets, D.L., Hennekens, C.H. (2006). Data Monitoring for the Aspirin Component of the Physicians’ Health Study: Issues in Early Termination for a Major Secondary Endpoint. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_7

Download citation

Publish with us

Policies and ethics

Search

Navigation